Hi, good morning. Welcome to the Kola project update for the Rocky release. I'm Eduardo, a PSTAC Kola PTL. My friend, Surya, let's go to what's new in the new release. First of all, what's Kola? Kola provides a production container ready for undeployment tools to pay out in a PSTAC deployments. The project is composed by three subprojects of PSTAC Kola, which is Docker images and building tools. Kola Ansible, which is the deployment tool based in Ansible playbooks to deploy OpenSTAC. And Kola CLI, command line interface and API to configure and deploy Kola Ansible environments. Project history, it was founded through the killer release. And then, one release later, during the VIN 10, during Liberty Cycle. And now, with Rocky, we're in the seven stable release. In the latest user survey, we increased a lot of production environments, 115 production environments with Kola Ansible, and 25, only the Docker images we produce with Puppet, Nomad, and other deployment tools. Just a small note, these deployments are only from the English hardware. So all the Chinese are not translated to English yet. So probably it's going to be much more deployments for the release. For the Kola images, we have added eight new Docker images for LogStars, Monasca, Prometheus, DraftD, Neutron, InfoLogs, IPI, and Driver, and Apache Storm. We also have support for BlueStore in third cluster, which supports both BlueStore and legacy storage systems. In the Kola build scripts, we also support now network mode, so you can define if you want to use NAT or Nethost for image building. We also have decreased the size of the images a bit by removing documentation from the packages and not just packages in the new releases. And also, we now include security updates for every package we install. The Ubuntu-based images have been upgraded to Bionic Release, and we have added new Neutron drivers into the Neutron images, like networking ansible and networking body metal.   Our daily builds also include the latest security updates for the packages. For the future in the Kola images, we aim to optimize a bit more the images to decrease the size and remove all the packages. We are also planning to migrate to Python 3. This is not going to be soon, because many OpenStack projects don't support Python 3 yet, and there's also no OpenStack distribution supporting Python 3 yet. CentOS is not supporting, so we cannot move everything to Python 3 yet. We aim to provide more CI jobs for the images before pushing to Docker Hub, so we can ensure more services are tested before having the images I've seen for consuming. We also aim to provide more CI jobs for third-party tools for Kola images users, like TripleO and OpenStack Helm. We need volunteers to do this job. TripleO has already pushed a patch for this, so they're just testing the images and more CI jobs for pushing the images. Hello, everyone. So what updates we have from Kola and Siebel side? So in Rocky, we supported the safe BlueStore OSD, and by default, we are supporting for now the OSD types only. Maybe in the future, the other types of the storage will be supported by the SAP itself. And some of the new roles for the OpenStack services is added in Rocky, like Freezer Sedular, and Apache Kafka, Apache ZooKeeper, and Partial Momonatska. For now, it is done, but in Rocky, we supported a Partial one. And we talk about the zero downtime upgrade. So in pretty much a stable stage, we have for the glance service, Cinder and Irony. And some of the more core services is implemented for the Stain one, like Neutron, Noa, and Swift. So in Rocky updates, we have these tables one. And if you talk about the monitoring for the open source tool for the monitoring purpose, so we supported in Rocky Prometheus, which is very much popular as an open source tool. So we have the role for Prometheus one too. And now you can restrict the limits on the container image with the help of COLA Ansible roles at the runtime. So you can restrict your resources up to limit option provided by the COLA Ansible script. And we also have now developed to the providing the developer option for OpenStack core services to create your own development environment into containers itself with the help of COLA Ansible script. Now, some of the changes that we did in Rocky in the Neutron. So you can see the ML2 plugin. You can have OpenVC, Linux, Beige, or Hyper-V L2 agent. So you can now customize with COLA Ansible script for the Neutron service. And if you talk about the info blocks, IPM driver, so it's used for the Neutron subproject intercommunication, so you can configure the driver of the info blocks in Neutron COLA Ansible role itself. And the Open Networking Operating System is also supported. So here you can do with the COLA Ansible script also. And networking bare metal is also comes into picture with the same supported by the Neutron project. And you can do some user local setting for the horizon project itself that enables you to debug some of the JavaScript and CSS level codes in the horizon itself. And we also added some of the more option in the COLA Ansible CLI. So it is like fork, check, and if. With the fork, we added for the large amount of deployments. So it makes sense adding the fork and doing the fork for the Ansible model. And for the check, we added this option with the COLA script to run your mock test after the post-deployment. As we already did in the pre-check before deployment of the COLA Ansible, so with the check, you can run your mock test after the post-deployment. And if you talk about what is the future of the COLA Ansible, so we are targeting these are the features that we'll be talking for a stay in or a train cycle. So fast forward is a priority one that we are looking for the next release. And zero downtime upgrade for the all core services as well as some of the supporting services of the OpenStack. And CI improvements is very needed for these deployment techniques and features in the field of upgrades, as well as some non-core projects, deployments, and running the functional test in the CI itself. And we can use Rally, RefStack, and Tempest to automate our testing in GateJob. And we are also targeting database backup recovery, restoring tools with the help of COLA Ansible, when your control base and database allows and how COLA Ansible will cope up with that. And COLA dashboard is one of the features that you can expect and which is, we'll be doing the POC for now. So that is for a very good interface to get the deployment with the help of COLA Ansible. No, our community is no single vendor community. So we have a lot of diversity and no company owns more than 20% of the contributions. We are the global distributed community with many contributors from Asia, Europe, and the US. In the ROCK Release, we have 125 contributors contributing COLA Ansible and almost 160 reviewers with nearly 5,000 reviews in ROCK Release. We have 720 commits in ROCK Release. 80% is done by other contributors, which means no single company owns the code, so it's a good number to know. We're going to join the team. Our IC channel is OpenStack COLA and Free Node Network. Meeting Suicide at OpenStack Meeting 4 on Wednesdays, 15 UTC. You can ask anything at the mailing list with COLA Attacks. And books, reviews, and patches are welcome. Filtered by Wesley's in EC Physics at Launchpad. You can start with FAST and ECFIX to start contributing into COLA. Thanks to all the contributors who made this release possible. Thank you for coming. Any questions so far? Any questions? Easy. Thank you.


My name is Chiu Yongliu from China CDC. My research focuses on two areas. The first is vector and vector bone disease. The second is clamping health risk assessment and adaptation strategies. As a postgraduate student, I learned a lot. I think I have the responsibility to teach what I have learned here, to empower young scientists to work together more effectively and efficiently. Thank you.


Aloha, I'm Jay Fidel, here on a Friday afternoon at five o'clock. And we have our very, very special five minutes at five, five at five at the World Conservation Congress every weekday while the Congress is going on. And our star of the show is Anu Hiddle. She's the host of our show called Climate Change Beyond Outrage, which plays on Tuesday, or Wednesday, I think, was it? Tuesday, Wednesday. And today she's giving us a special report from the Hawaii Convention Center on What's Going On at the Conservation Congress. Welcome to your show, Anu. Hi, Jay. Aloha, everyone. So I'm here at the World Conservation Congress. And this is day two of a 10-day conference, 9,000 people from all over the world. And this morning, what I really, what drove home was that this is a different beast from, say, the United Nations Framework Convention on Climate Change, which is what I'm used to covering. So this is different because NGOs, non-governmental organizations, and governments get together and it's not just the governments making decisions and policies for conservation. It's all of these people, really, it's citizens, members of the International Union for Conservation of Nature. And this is the place where the global agenda is set. This was driven home to me today because very high-level official, the highest in the UN system for the climate meetings, Patricia Espinosa came to the IUCN and she was on a panel with other folks. And they were really talking about climate change, but this is not just about governments talking to each other. So it drove home to me just how different a beast this one is. Still a beast, but different. So that was the first thing. Now the other question you might ask, Jay, is what is the global agenda for conservation? And yes, I knew you were sitting and waiting for that one. So this is something they're crafting. There are about 100 motions, a little less than that on the floor. Starting on the 6th of September, they will start talking about some of these motions. The rest have been voted on electronically. And then what I was thinking about is that, you know, so they will vote on these motions, but these motions are really quite different from what you might imagine. They're not just about nature or what you might think of as nature. So they actually include, ta-da, human beings. So apparently we are part of nature. So, but this is seriously, this has been a dichotomy amongst conservationists and people who are not necessarily conservationists in the traditional sense. Okay, so really the international union for conservation of nature includes people and they're making a big push towards trying to advance the sustainable development goals that were set forward in September of last year by the United Nations. Can you give us some examples of the motions, both on the people side and on the environment side? I will in just a second, but what I was getting at with the Sustainable Development Goals is that goal number one says no poverty, okay, so it doesn't have, it doesn't come out and just say nature. It says no poverty and that has to do with people. So this, they're really making a push to just, to include, to make everyone understand that this is about everyone and not just about saving plants and animals, okay. So for example, as I mentioned, there are motions on the floor about specific species such as the Amur tiger or the Amur leopard in Northeast Asia, but there are also motions on the floor about building networks or looking at domestic markets for ivory and so on. So it really does involve people and their sustainable livelihoods. So this is something that I think is very interesting and exciting. Of course, the highlights are also, I would be remiss if I didn't mention that father of biodiversity E. O. Wilson from Harvard University was here, he just did a press conference. I have questions, a couple of questions into him, so I'll be sending you some footage on that. And I just barged in on a private interview being taken of Jane Goodall. So I just got a photograph and nothing else, but they shoot me off after that. So anyway, so those are the highlights for today. And I would say that it's been really exciting. There are many people around milling about, again, people from all continents, all six continents. Very, very exciting, Anu. Very exciting to have you there and to get your reports every day. We sure appreciate it. And we are with you in spirit and in video. Thank you so much, Anu Hiddle, who was the host of our Climate Change Beyond Outrage Show during the week and who does every afternoon, during the continuation of the World Conservation Congress, five minutes at five. Thank you so much, Anu. Aloha. Namaskar and goodbye. Aloha.


Big update to the 232nd combat training squadron as we've moved from Creature Force Base to Nellis Air Force Base to fully support the Warfare Center mission at both operational tests, maintenance in the F-35 Bolt AMU and the NTTR Nevada Test and Training Range organization specifically in the 31st combat training squadron supporting the virtual test and training range. The biggest thing for Nevada and the one Nevada construct is the opportunity that the 232nd provides is limitless growth based on our active duty demand signal to fully support and integrate across all aspects of the United States Air Force Warfare Center mission supporting both air and cyber.


I would say if you ever have a time where you feel that you need extra support with your mental health and well-being, please do come and speak to your student advisor because our role is really to talk that through with you and then identify what might be the best support service available. And at the university we do have different options. We have a student well-being service with a well-being advisor who is specifically assigned to the business group. And we have a student counselling service who have excellent self-help resources on their website and also one-to-one counselling available through the counsellors. There's also the listening service through the chaplaincy, which is a non-judgmental space to have one-to-one conversations and all kinds of things. And the chaplaincy centre also have excellent resources on their site and their applications. I think my main message is we are here in my job to help. So please don't suffer in silence. If you think that something's stopping you from when you engage with your studies or your face in difficulties, you will be able to find a solution to that obstacle.


Hello and welcome to NewsClick. The U.S.-India trade relationship has grown steadily over the years. In 1999, the total value of trade and goods and services was $19 billion. In 2018, it's now at $142 billion. But despite this, the trade relationship has been marred with disputes on several issues from tariffs in agriculture to intellectual property rights to tariffs on Harley-Davidson bikes to the H1B visa to India's policy on e-commerce. And maybe that is the reason why, when Donald Trump makes his maiden presidential visit to India on 24th and 25th of February, it looks highly unlikely that a trade deal will be secured. To find out the reasons for the impasse in terms of the trade deal, we have with us Dr. Biswajith Dar, who is professor of economics at New Delhi's Jawaharlal Nehru University. And we will speak to him about what has been happening on the trade front. Dr. Dar, welcome to NewsClick. It looks like in terms of the political and strategic front, the relationship is on an upward trajectory. But despite several months of negotiations to secure what has initially been called a small trade deal or an interim trade deal, reports indicate that this deal will not be secured when Trump visits New Delhi on the 25th. I want you to sort of put this in the context of balancing the political strategic with the trade relationship, but also in the broader economic context where you see a rise in protectionism, you see trade deals being hard to secure. The US is withdrawn from many trade deals. The WTO is at an impasse. India is also withdrawn from the mega FTA, RCEP in November. So, how do you sort of see this in a sort of broader context? Yeah, I think you just said the context because India-U.S. relationship is particularly strange, I would say, for want of a better word. Because if you look at the political strategic side, then for the past more than a decade now, since the signing of the nuclear deal, the relationships have been just moving in one direction. They have been going up. And India is now firmly with the United States on most international issues. And so, many of the past differences have been ironed out. But if you just turn and look at what is happening on the economic issues and the economic relationship, I think it had always been contentious. And in the past few years, I think the level of contentions have gone a few notches higher. So, we have a strange dichotomy between the political-stroke-strategic relationship and the other economic relationship. And to my mind, it is happening because of several factors. The first is that India is one of those countries having very large market with whom U.S. actually has a trade deficit. And conversely, one can say that U.S. is one of the few major economies with whom India has a trade surplus. So, given the fact that U.S. has the largest trade deficit among all the major economies, in fact, all the economies have the largest trade deficit, and it is very keen to reduce its deficit and to find better access for its producers in these large markets. So, there is a certain degree of anxiety that U.S. has in terms of finding the Indian market. So, it has been pushing. So, I am looking at the good sector. Now, on India's part, India has been running trade deficits and the reason for us to be the situation is that our manufacturing and agricultural sectors are in a pretty dismal shape. And this was the reason why there was a pushback from the domestic constituencies when India is negotiating this mega-regional RCEP, the Regional Comprehensive Economic Partnership, because there is absolutely no appetite for any further liberalization. And this any further liberalization would mean death knell for all these Indian producers. So, you have a situation here that and again, if you look at the way government of India has been dealing with the great trade policy, it has been increasingly going protectionist. And this started about a couple of years back and if you look at this year's budget, this year's budget is all about trying to protect markets and trying to monitor imports as much as possible, because the government I think is mindful of the fact that exports are not growing and imports are sort of could go out of control. And therefore, the balance of trade will go so high that the current account will get jeopardized. So, the reason why this has not happened, this deal that you are saying that despite negotiations for several months, the two sides engaging for several months, there has been no movement is I think the fact that India is extremely careful and taking each step very carefully. And I don't think that we are going to go anywhere near doing even the minimal kind of a thing that the US is expecting. So, Dr. Dhar, if we can just get into the details of some of these areas where you said the contentious issues are quite deep and maybe start with agriculture, because that's been an issue where you already have letters from farmers movements, you have the AIKS has issued a letter, the Indian Coordination Committee of Farmers movements have. And Trump is, I mean, the USTR has already put out a list of products. And like you said, in an article that you wrote a few days ago, you've said that India's average tariffs have gone up over the last two years from 13 to 17 percent. So, what is it that India will do on agriculture and where do you see specific concerns in terms of all those products from almonds, walnuts, dairy, peanuts, soybean, wheat, all of these issues? Yeah, I think that's where things get absolutely, the real problem area is when you look at agriculture and that's where things become extremely difficult. Because US has been losing, has lost his edge in manufacturing. It's almost giving, China has taken over its manufacturing market. And therefore, the only strength that US has today, realistically speaking, is in agriculture. So, it's actually the largest exporter of wheat and soy or maize and all those products. And therefore, it is very keen to find this market. It's also linked to very high subsidies as you've written about. Exactly. So, I was going to come to that. And the reason is that the question one should actually ask is that how does US, which such a resource intensive agriculture, how is it able to maintain that kind of a stranglehold over the international market? And the reason is simple. We have been talking about for decades, the high doses of subsidies that are given to the, it's no longer small farmers, it's actually corporate agriculture which dominates the scene. So, that is what is happening. Now, on this issue, there's some interesting play going on between the, from side of US, I won't say between the two countries, but from the side of the US, which is that US is aware of the fact that if it pushes India to lowering tariffs on agriculture on all these major cereals, then there's going to be a flat no. And the way we negotiate it into the WTO, the World Trade Organization over the past two decades was very simple. India, when it came to reducing US asking India to reduce tariffs, India's straight response has been that if you guys reduce subsidies, then we can move our tariffs.  So, it's very clear that with this kind of sort of negotiating counter, US would not get anything from India by way of additional market access. So, US has actually played a very interesting, you know, has, is playing out a very interesting card in the WTO, which is that it's questioning India's subsidies to the two major crops, wheat and rice. And as you know that India is basically a wheat rice economy, overwhelming large share of Indian, you know, the cultivable land is devoted to producing these two crops. So, which means that substantial number of farmers are engaged in production of these two crops. And then of course, it's very important for us because it's food security. And with the great deal of difficulty, we came to a situation where we can at least on paper call ourselves self-sufficient and we are self-reliant in agriculture. But of course, we need to do much more. So, now in the WTO, US has said that India is giving much more subsidies to wheat and rice than it is allowed under the rules. And so, their logic is very clear. They would like the WTO to come down heavily on India, as agricultural subsidies program, force India to reduce subsidies. And if subsidies are reduced, you know what's going to happen in the viability of Indian agriculture. And here we are talking about small and marginal agriculture. So, subsidies are used by both countries. One country uses subsidies to exploit markets, to penetrate international markets. The other country is using subsidies for food security. So, you know, these are at two very different levels. But WTO doesn't make this distinction. And we've been arguing that this distinction should actually be made. So, if the US is hoping that WTO does something to discipline India, and then it's going to be curtains for India, if WTO really comes down heavily. And is that the reason why there's been the removal of the GSP status, the generalized system of trade preferences? You also have a few days before India has been removed from the US's own definition of developing countries. There's been, like you said, in the WTO, an attempt by the US.  But on certain elements, they are quite active. Removal of special and sort of differential treatment for countries like India. It's also an arena in the UNFCCC on climate talks where they want India and China and other big countries not to be recognized as developing countries. So, what is the sort of tactic that India will use to maintain its subsidies, but also its status? And that's something that I guess will be on the table because the sort of slapping of countervailing duties provision just came up a few days ago when it was removed. That is right. Again, the US, I won't even say a long term, but even sort of short to medium term strategy is to get the WTO recognize India as a developed country, not as a developing country. But unfortunately, WTO rules say that the countries actually self-designate themselves. And that's where the onus is on us to really spell out whether we are developing or a developed country. We have actually been calling ourselves a developing country. But the sentiments are very mixed here because a lot of people here would like India to be called a developed country. They won't actually want us to be with the poor, poor countries. They would like us to be a part of the richer block of countries. But this is strange. I don't know how people actually make that kind of an argument because if we look at India, a small part of India is actually a developing country, but a larger part of India actually looks like a least developed country. The kind of poverty we have, the kind of malnourishment we have and the development deficits that is all pervading and it's not decreasing, it's actually increasing. So I think Government of India will have to be very clear on this because the onus is on Government of India, whether or not to take the bait. So US has been doing all this, has been wanting to get India deregognized as a developing country. As you said, the first thing that they did was to remove India from the list of countries that enjoy trade preferences in the US. Simply put, developing countries get that advantage of lower tariffs for their products in the US. So therefore, they can enter more easily as compared to the developed countries and this has been going on from the 70s. So last year, US removed India from that list. This year, what they have done that there is an agreement in the WTO on subsidies and countervailing duties and this simply means that when some subsidies which are used by countries and these are part of exports and the subsidies are used to also export, the importing country can impose a countervailing duty, a matching duty which will neutralize the use of subsidies. Thanks a lot Dr. Dhar for taking us through, I mean the very complicated terrain of trade policy negotiations and getting into the details of specific issues. We'll come back to you post the visit if something else comes out of it. Thank you very much. Thank you for watching NewsClick and like I said, post the Trump visit, NewsClick will be sharing our analysis through our website and through the YouTube page. Thank you.


Welcome to Access to Trader, the number one community for those who are committed to taking control of their trading in order to achieve success, profitability, and longevity. Thank you for joining us. Here's Dan Shapiro to help you find your edge, master your process, and own your future. Hey, guys. Good morning, everybody. Welcome to another edition of theaccesotrade.com weekend update show. Hope everybody's having a great weekend. So it's going to be now, I think, 21 years for me in March. And I will say this much. This past week was probably one of the more craziest weeks that I've seen in an incredibly long time. Now you have to take this into kind of a condensed version of my career. This is a pretty big statement considering that some of the biggest moves came from the internet craze 9-11. 9-11, if you guys remember, the market was closed for a week. They opened the Dow down 1,000. Next day was down another 1,000. It's pretty big moves. Traded through the mortgage mess with all the Bear Stearns and Lehman Brothers and everything else in between, crazy, crazy moves. But if you look at this week, there is not that many weeks that you can turn around and say, the last day of the week, the Dow was down 250, 300 points. The Dow was still up 3%. The Nasdaq was still up 4%. The S&P was up 4%. Not only that, you had one of the more arguably, arguably, and anybody's generation, one of the more incredible five days of price action that we've seen, that I've seen personally just in Tesla. These are five days. This isn't five months. This is five days worth of action. You still have an incredibly important health scare on the table. Again, every single time you think the market is slowly but surely negating it, you're getting that feeling. Again, hence the 3-4% moves all across the board. One headline comes out. There's a new death in a certain region. The next thing you know, the market starts to panic and sell off again. When you have a market like this and market structure breaks down out of nowhere, it's very, very tough to navigate core positions. Again, everybody's way of trading is going to be different. I am primarily channel trader. I trade within channels. The macro picture for me is important, but not as important as what I can get throughout these channels. Some of these channels could be $2. Some of these channels could be, like Tesla, $80. Not normal, but they could be. The most important part for me is having the ability to understand and appreciate the risk appetite within those channels. If you're trading, for example, on a macro area and you trade through daily charts, you're going to have a completely different outlook. When you're looking at the market from this point of view, and let's talk about the NASDAQ 100, you can make a very, very bold case that everything is fine. Everything is fine. I agree with you on the surface. Again, I always play doubles advocate because the last thing I want to do, especially for all our friends who trade on a bigger macro scale, is give you my view that I don't believe is real. I do believe Wall Street has a tendency to make you feel comfortable. I do believe what sometimes you see on the outside is real. I believe that. But also, I do believe the consequences of being arrogant, being blinded by the light, wearing the blinders and all that good stuff.  These are very, very hard and these are very hard pills to swallow because, again, you're not sitting there trading within a channel. Your time horizon can give you a much bigger exposure to the wrong side of the market than it is to mine. So it's very, very important to really understand where we are and just really understand all the dynamics of what we're seeing in the market. Super aggressive, right? Super aggressive. I don't think there's a doubt that the buy-the-dip theory for the most part is real. I think personally it's almost like cartoonish-like. It's almost like a myth because, again, it only works when actually there's a good market sentiment stocks go up. Again, the idea of buying the dip in a freefall market just doesn't make sense and nobody does it. Again, it's the only business in the world when things are on sale that people want to buy. But again, when you're in an upside market, when you're in a linear market and you're in a bullish market, it makes sense because, again, that is what you're seeing. That's the right thing to do after the fact. So we're going kind of into this week. There's a lot of questions going around. Again, nobody can deny the market strong but, again, for how long? And again, the reason why I say that, if you look at the Qs, despite some pretty good results from a lot of companies, Microsoft and Intel and Apple and Amazon, we'll get to Amazon in a second. And the sheer euphoria, the absolute euphoria of a Tesla, it's very, very tough to argue that the next phase of the market is higher. But when you look at this massive, massive view, you're trying to say how long can the bulls hang on for life. And again, sometimes you can't tell through the macro channels how a market is playing out. And sometimes this is, again, where it's so beneficial to kind of use a different channel. And if you see here, for example, you have three, four days of consolidation on the Qs, definitive channels to the downside, definitive channels to the upside, you can't really get that sense of this macro view. Again, you can turn around and say, well, Dan, well, it's very, very easy. Look at the top of the channels here for the last three days and look at the bottom. It's not that obvious for a lot of people. And if you look at channels, for example, for the names that had their bigger moves, for example, the apples of the world, we talked about five, six days of really, really aggressive moves. And now, again, they're kind of going towards the bottom of the channel, towards the top. The video, again, one of the bigger, bigger movers the last four days of the market, excuse me, when the Qs were up, and that's because it was a 4%, we're down to the bottom of the channel here as well. Same thing, for example, with an Alibaba, same thing, for example, with an Alibaba, same thing, for example, on a square that had a very, very big move, right? And now you have four or five days of kind of trying to get out of the channel and then kind of falling right back. And the same thing over and over and over again, especially names, for example, like Apple had that really, really big run. Again, nobody's saying the stock's not going higher long term. I love Apple has the most money ever in the history of the universe. But again, we're just talking from the point of the trading aspect near term. Again, nothing is promised tomorrow. Hell, we're not even promised to wake up tomorrow. So the idea that somebody could turn around and say, well, Apple's going to be at $400 a share next year. Okay, God willing, let us live to find out, okay? But what we're talking about strictly from what comes next, what's the possibility, the higher probability, what might come next. And again, nobody's saying the market's going to go lower. We're just talking about where these stocks are, where the macro stocks are, the strength channels are, the stocks that had really, really good earnings, where they are in the last four days as the NASDAQ composite was making a 4% move, right? They're not at the top of the channel. They're all at the bottom of the channel. So it's something for us to really have to pay attention to going to this week, right?  Again, nobody knows what's going to happen on earnings. But if you look at stocks like this, this is a little bit more easier to figure out, right? This is a little bit more easier to kind of digest where the possible next move up or next move up or down. But again, you can't make that statement until the price action occurs. Stocks like NOW, again, had a big, big run. So again, nobody is talking about the long-term perspectives on NOW. But what we're talking about, again, is where the market is, right? And where the stock is in the bottom of the channel compared to the market. Again, I understand markets, you know, markets resting, the stock is resting, had a big run. We get that. Again, we just want to put our friends, our social media friends who are not with us, who don't participate in the live webinar every single day, we just want you to be conscious of the fact that there are ranges there. When you hear me talk about sneaky ranges, sneaky channels, sneaky channels, when they get confirmed, they start testing the upper range. They start testing the bottom range. And that's what we'll talk about in a few moments of what happened on Friday's pivots. So just be conscious, okay? Be conscious. Don't be naive that the market can't eliminate all your gains. Don't be naive that gravity is not real.  Again, this business is all about reality. It's not about perception. It's not about your opinion. It's not about what's going to happen three years from now. Yes, I get it. Amazon will be at 5,000 three years from now. And again, we'll talk about some call buying in a minute. Very, very aggressive call buyers. And matter of fact, this was actually a phenomenal move on Friday. We'll talk about that in a minute. But again, if you are especially a newer trader and, again, your swing trader, whatever you are, okay? Just always play devil's advocate. Okay? Always look at not necessarily your positions. Okay? Look at the most aggressive speculation money positions out there. And even if you don't trade stocks like Microsoft and Apple and NVIDIA and Alibaba and Facebook and Google and stuff like that, at least know where they are in the cycle. Because again, remember always this. If speculation money is in a buyer strike on the bottom of the channel, if there is a downturn and again, very, very possible with all this whole health scare. Those are going to be the stocks confirming first. And if you are along those stocks at the top of the channel and you're not aware that they're about to crack support and confirm going lower to test macro levels, you're going to be in a lot of trouble. So something like this, you know, especially on the weekends, it only takes, I would say it only takes about a half an hour of your time. So look at the macro market. Go through charts. It'll take you what? Five minutes to go through the members of the QQQs. It'll take you what? Three minutes to go through the Dow Jones industrial average, right? S&P 500 maybe will take you 15 minutes to go through. So you have a half an hour commitment to really understand a macro point of where the market potentially could go next. Okay? You always want to be a step ahead of the market.  You're not prepared and your positions are going to be bleeding very, very aggressively. So a little piece of advice going through this new week. Again, I'm dealt a neutral, okay? I'm dealt a neutral going through this week. I'm always cautious that they can't pull the rug. But again, we discussed this level. So if you've been watching kind of the broadcast now, just for the last several days, I mean, you kind of know my thought process by now. Again, we have the definitive channel here that we're watching in the QQs, right? We've been talking about this bottom channel here for several days. And if they close below the five-day moving average, again, it might not be obvious to a lot of people because most people don't celebrate the five-day moving average. Again, every trader uses different days.  I use the 5, 10, 5, 10, 20, 50, 100, 150-day and 200-day moving average. Both EMA, SMA, I use the linear regression lines, the Bollinger bands. I know that's a lot of information, but these are the things that are going to always protect me from the surprise element. And again, very, very understandable from the macro point of view. If we lose this, you know, 227.40s, 227 level on the QQs, this is where, again, if you are using a portfolio approach, maybe you just want to start either buying downside protection via the options market or kind of eliminating some exposure off your book. So, crazy week.  We saw what happened with Tesla.   So, I missed that whole big move. And if you guys remember, I was okay with that, because I've always maintained the fact that, again, the market gods will give you what they give you. Remember that video from Wednesday? And that's how you quickly eliminate the fear of missing out. You really just have to understand that whatever is meant to be is meant to be. It's like almost like going into the park and meeting your future spouse. If the universe is there to facilitate that, it's going to facilitate that. So, yes, it's swallowing a pill missing 150-point move down on Tesla. And let's be honest, I'm going to hold the stock for 150-points. So, it's really not that horrible. And the most ironic part about it is, I had the fear of missing out completely out of the way. It's almost like I adopted the joy of missing out, right? The Jomo. And the next day, I caught Tesla for a 12-point candle. And again, kind of a side note, what's happening on Tesla. Just a quick side note, because I want to kind of go a little further here. If you notice what's been happening for the last three days of Tesla, you guys notice how tight it's starting to get, right? So, the next move, you don't even need to guess. And what I like, the fact that it's getting a little tighter, when I mean tighter, it's only going on $20 intervals. But what you notice the last three days is getting really, really tight. Top of the channel, bottom of the channel. Something's going to give here. And again, we have very, very sneaky channels here to figure out what it is. So, for the next several days, guys, you don't even need to guess. You don't even need to have an opinion. All you perma bowls, all you perma bears on Tesla, zip it. We're either going to break above this channel or break below it. Again, nobody knows what's going to happen. You can guess. You can argue. You can spend a lot of mental equity, wasting your time trying to figure it out. But the market action is going to confirm eventually, whether it's tomorrow, whether it's Tuesday, Thursday, next week, whatever the case may be. But there will be a very, very definitive trade in the stock. And all you need to do is wait. But the point of the matter is, again, you don't need to chase the rainbows. You don't need to try to squeeze water out of a rock. Let it come to you. Let it come to you and the trade should facilitate. If it's confirming technically, it's going to facilitate. And the most ironic part about this whole move here, and yeah, I mean, I caught bits and pieces, you know, on Tesla here and there, here and there, here and there. That's kind of what I do. But the most amazing part, the best value of the week was Friday. Right? It was Friday. You know, let's talk about it Friday. And this is kind of, again, where you look at, where is your best area that you could lay down your money that is going to have the smallest amount of exposure based on technical analysis and where you can strike with an incredible amount of aggression knowing what your max pain of technical analysis is. And Friday turned out to be a really, really good day. Definitely my best day of the week. Let's talk about it. Right? It was all facilitated on BYND and Amazon. Amazon as well. So let's talk about it. So I want to actually start out with, I want to start out with pins. I think for three days in a row now, I think it's even two or three days in a row. For some reason or other, I've been really over, I've been really, really for some reason jumping out of my shoes in the first like couple of minutes of the trading day. It's very, very annoying. And I've kind of identified the problem now. And I have to stop. For the last two, three days, I think it was two days, maybe it was three. My first trade of the day has been raw, like literally two, three days in a row, because I'm not letting the stock kind of play out. And on Friday, if you notice, I put in a pivot here on pins. Pins came out with earnings gapped up and it retraced into rising support, right? And this was a natural pivot. So it never got to the natural pivot. So all you guys who are on the Twitter feed, you don't even know what I'm talking about. But in the webinar, I said, hey, if this thing can come back into the 27 area and remount, I think the stock's going to go. And if you look at the 60-minute view on pins, and again, this is where we talk about, you learn from trades that don't work out. You concentrate on those trades. Because again, for all you guys out there have been trading for at least a decade. And some of you guys have been trading two decades. I'm going on to your third decade. After a while, it becomes so normal that you're expecting technical analysis to prove you're right. But when you read something a little bit wrong, you get FOMO, right, instead of JOMO, right? Your results are going to be skewed because again, you're not letting things play out. You're kind of anticipating what happens next. And that's kind of what happened to me on Pinterest. So Pinterest had that spike, right? It had that spike to 2780. And obviously this is what we were talking about if it starts to build 2780, 28, right? It should go, obviously never got there.  So it came down to here, right? It came down to here and I did the remount right away. I did the remount right away instead of letting it go through and then take the remount. So I did the remount right away and I wound up losing 60 cents on the trade. Now again, it's not really the loss, okay? It's not really the loss that's blowing my mind. It's blowing my mind that I did this two days in a row on stocks that were coming off highs, into rise and support that I didn't let it play out enough that it can reclaim, remount supply so it could go back higher. So it's something I have to kind of pay attention to going into, especially tomorrow's day. Don't get too antsy and especially names. Again, if I miss it, I miss it. Just let it play out first. So what happened was it came back into this channel. I remounted it way too fast. I didn't let it push through first. And, you know, once it lost this area here, I got out lost 60 cents. Again, not the end of the world. It's just annoying, right? And then annoying. And then things started playing out incredibly well and this turned out to be an incredibly good day. So let's start off in the bottom to the top. NOW needs to build the 3.44 level. And if you notice here, if you notice here, right over here, I said, hey, make sure to take some off on the spike. It's having problems with the 3.45 level. So start right up about a dollar, dollar and change. And obviously take some off, use break even as a stop on the 3.44 build. And that's the whole point of trading, guys. Just kind of seeing the levels that they can't get through. And if you notice here, look, if you follow the Bollinger Band here, it was having problems, right? It went to like 3.45, 7.7, you know, off the 3.44 pivot. But it was having problems at that 3.45 level. And the longer it can't get through, it's not the idea of giving it the benefit of the doubt. Technical analysis is telling you it can't get through. Make some sales, use break even as a stop. And obviously if that was the case, you did well in the trade. Not great, but you did well in the trade. Enough again. Not every single trade needs to be a $9 move. But again, technical analysis is there to give you a guideline of what should happen next. And again, if you didn't listen to me at the 3.45 level and you saw this dot come all the way back in. But again, a trade is a trade is a trade. So let's talk about some other names. iRobot never built 59. I still like this iRobot going into next week. Again, we got to watch sneaky areas here. As you can see here, the height of the day here is 58.84. Needed a 59 area to remount. So set an alert, guys. Set an alert on this 59 level going into this week on iRobot FLGT. Again, another name you need to wait for confirmation. 1680-17 needs to build. Again, I still like it going into this week. Obviously, if you look at FLGT, it never got above that 17 level. Again, another stock that, again, it looks like it rested. Set an alert. Actually, you know what? As I'm doing this, I'm going to set an alert on FLGT. So FLGT, let's just set an alert together. So I don't forget about this thing for next week. 1690 for a 17 break. So again, follow the guidelines. Don't anticipate a trade. Let it play out organically. And this is where things got good. I mean, really, really good. This is a fantastic trade. Really, really fantastic trade. BYND and number one, nobody knows. Everybody has guesses. Pardon me. Everybody has guesses when they're supposed to come out on earnings. Nobody knows. But we've been watching BYND for four days in a row. And 114 has been like, you just can't get through it. It just couldn't get through it every single time it came up. It got exhausted. It came back down. So BYND several times got rejected and needs to reclaim the build. And kind of the background of BYND. If you guys remember when the whole BYND move started a month ago in the early 70s, there were buyers coming in for the 79s, coal buyers for the 79s, for the 95s, for the 110s, for the 120s, and then the stock made its move. If you saw what happened on BYND, if you've been watching BYND for the last couple of days, and again, it might be coal buying to cover the earnings. Just nobody knows when the earnings are. So we saw coal buying coming in short-term expiration, the FEBS, FEBS in some of the marches. But the 120s, the 135s, the 140s, we even saw the 160s come into play. And when you started seeing all that coal buying coming in on Friday, once that 114 went, this was a fantastic move. I thought it had a shot at first at 118. And the reason why I thought 118, because again, that's the top of the macro channel. But here is the 114, 114, 114, 114. So it got rejected several times 114. I got low on the 114. You could see the 60-minute channel, how aggressive it was, right? Excuse me, here it is. You could see how aggressive this whole 114 area was. And this is, again, this is what we talked about, sneaky channels. I thought it had a shot to 16, 16 in change. So I bought it at 14. My highest sale was 16, I think, 16. 16 or 16 in change, 16. I think it was 16. And it put in an opening range high of 117, right? It put in an opening range high of 117. And again, if you trade the PS60 theory, you kind of know every channel needs to be confirmed. So the next candle takes out 17. I buy it back, right? I buy it back at 17. And it goes to, like, 20 and a half. And my highest sale on that move was 19. So I was really, really happy with the trade. And then, again, there was, and one thing on BY&D, we were watching this thing the whole day. And then people just turn around and say, well, level two is not important. Well, again, how are you ever going to know there's a really massive reload buyer? There was a, guys, no joke. There was a buyer, for all you guys that traded beyond on Friday, there was a buyer for 30 to 50,000 shares every dollar up, 118, 119. I forgot about 20s, but the guy was a reload buyer everywhere. So, again, with all the call buyers, this guy was getting along really, really big on the equity. There's something we always ask, is he not uncertain? If the earnings are coming out, is he not uncertain? So, again, you could tell there's a really, really good sneaky pivot coming in here on Monday. Again, please come to Morning Strategy early. We'll talk about it hell. You don't need to buy it up here. This whole channel here is really, really good. So, really, I'm very, very happy about the BYND trade. Tesla obviously never got to the bottom of the range. Late day fade into Roku. I still like this price action for tomorrow. It went down to like 23.75, but I think this channel needs to be confirmed. It went a little bit low towards the end of the day. Boeing never got to the 342 level beyond, again, just a big, big move, take along the way. Just a huge move and, of course, one of my favorite gifts of all time. You guys remember that 80s commercial? Where is the beef? There's my girl. Where's the beef? Again, make sure you take along the way. SDC keeps on getting rejected off this level here. It needs to reclaim 15. Again, for all you guys who have been watching this stock, it really does need to reclaim that 15 area. It needs to build aggressively. Tesla to the upside obviously never got there as well. So, oh, Amazon. So, I caught Amazon pretty well on Friday. Where's the Amazon pivot? Did I not put the Amazon pivot here? Where's the Amazon pivot? Where the heck is the Amazon pivot? What happened to my Amazon pivot? There was an Amazon pivot.  That's a great question.  I don't know. I don't know. Let me take a look at my other account. It's a great question.  Did I erase it by accident? Why would I erase my Amazon pivot? Let me take a look here really quick. So, there was a very, very... When I find this thing, let me just show you guys. So, we were watching Amazon for three, four days. Big, big consolidation channel, right? Really, really aggressive consolidation channel on Amazon. And we were watching it for three, four days. The only question was, the only question was on Amazon. Was it... Oh, yeah, here it is. I don't understand what happened to my Amazon pivot. So, right. So, here's the pivot. Yeah, it's on the Twitter feed. I don't know what happened to it. Yeah, so I put this into the Twitter feed. 907, 907. And 2059, 27. Maybe it finally wakes up in this lifetime. Again, if all you guys have been trading Amazon for a long time, you kind of know what I'm talking about. It makes us move and it does nothing for like a month. So, we were talking about this area here, 2059, 2060.  It gets to the 2095 area. The reason why, if you look at the chart on Amazon, excuse me, if you look at the chart on Amazon here, you'll see why, right? You'll see why here. So, here's the 60 minute view on Amazon, right? This whole sneaky channel here, the top of the channel here was this 2058 area. So, I knew it had to get, you know, I knew it had to build a new base above 2059, 2060. And this thing exploded. I mean, just absolutely exploded. Look where it went to. It went to 2099. So, the macro pivot, that's where it needs to relocate, to rebuild, but you see this whole area here, guys? We're not waiting for that 2100. This thing takes out this whole little baby channel here. Again, this is what we talk about, the sneaky pivot. This thing's going to go back to test that 2100. So, really, really great move on Amazon. I was very, very happy with the trade. I know a lot of you guys did very well on it. Let me see what else we got here. Let me see what else we got here. Let me see what else happened here. Let me see what else happened here. Microsoft buyers. Yeah, and the one thing just to kind of a side note on Amazon, there was a lot of really aggressive call buying we saw this week on Friday. We saw buyers come in for the 2400 calls. We saw buyers coming for the 2700 calls. You can see here, I actually was tweeting it out as the stock was moving on here, a $1.6 million bet coming in for the 2100 calls. But there was some really, really aggressive call buying, not only just yesterday throughout the whole week, so now you're starting to see where your measured potential is, 2400, 2100 for the next week. So, again, as long as this health scare doesn't really get too aggressive, there's still a lot of good names out there. A lot of names are just finally waking up and the most important part is just to make sure you wait for the price action. For all you guys who are trading with us tomorrow, who are new, whether it's on the private Twitter feed or the live webinar, the Twitter feed starts up about 9am. If you are joining us tomorrow, please get to the live webinar at 9am. We're going to talk about all the pivots. There's a lot of really tight action, tight channels that are forming on Tesla, on Amazon, on beyond. Hell, even on Facebook. Look at Facebook. Look at Facebook here. Check a look at Facebook. And again, not really the greatest name in the world, but look how tight this channel is, right? Just to show you how tight these channels are. So please get to the live webinar early. We'll get through everything for all you guys. Have an amazing trading week. Stay disciplined. Stay focused. Half faith. Your time will come. It's all about experience. It's all about having the ability to stay solvent and stay in the game. Guys, God bless. I love you all. See you on the field tomorrow. Congratulations for putting in the time to take control of your trading. You're one step closer to owning your future and achieving the success you desire. Want daily trade ideas directly from Dan? Straight off his personal watch list? Unlock our free PS60 vault, where you'll get nightly updates on pivot opportunities we're watching for the next day's session. Click the link in the description to get started today.


Hi everyone, Joe for Jaspy's casebreaks.com coming at you with 2020 Clearly Authentic Baseball. It's a one box break, random team number eight. Now, at the end of the break, we re-randomized the original 14 names. And the name on top will win a box. I guess this will mark these one and two. So the name on top will get a box. And I'll roll the dice to see which one you're going to get, box one or two. And then the second name will get the other box. But we'll do that as a separate dice roll at the end. We've got another one of these up. Break nine is already up. Don't sleep on these, folks. There's a lot of incredible dynamic dual autographs that are in here. Each box contains a dual autograph. And there's some parallels there, too. Could be one of ones in there, too. All right. Let's do the Clearly Authentic Break first. Big thanks to these folks here for getting into the action. Let's double your names up.  I think we comboed the royals and marlins, and we took out the pirates. So there's no pirates here. When there's royals and marlins, combo it up. So let's roll it and randomize it. Snake Eyes, two times. One and two. After two times, we've got Jack down to Diane, Jack and Diane. And then Snake Eyes for the teams, one and two. We got Rocks down to Stroze. All right. So Jack with the Rockies, A's Mets, Ryan with the Phillies, Diane with the Brewers, Jack with the Indians, Steve with the Cubs, Anthony with the Reds, Jack with the White Sox, Diane with the Jays, Joe with the Padres, Steve with the Giants and Orioles, Alan with the Royals, Marlins combo spot, Anthony with the Cardinals, Ryan with the Nats, Alan with the Rangers. Johnny, you got my Dodgers, Jack with the Mariners, Lauren with the Angels, Steve with the Rays, Joe with the Diane back, Steve with the Twins, Lauren with the Braves, Steve with the Tigers, Diane with the Red Sox, Johnny with the Yankees, and Diane with the Astros. Any trades. And once again, we'll randomize that original list to 14 to see who's going to win those on-demand boxes. No trades? Maybe not. Trade window closed. Time to go. All right. TWC, trade window closed. Let's print and let's rip. Got Cleveland at Pittsburgh on in the background, little exhibition action, scrimmage action. There's the final list right there. All right. Good luck. The encased card is going to be in Oakland A, Jesus Lizardo, rookie autograph. Kind of hard to see his autograph in that lighting, but that's for the Oakland A's, Jack with the A's. All right. There you go. Let's do the randomizer for that. There's our schedule right there. So we took the original 14 names and let's randomize that. Top two after three. Top two after three. One, two, and three. After three times, we got Allen and Jack. There you go.  So, Allen, you're going to go first. So we're going to use that die right there. One, two, three for the left side and four, five, six for the right side. And then obviously, Allen or Jack, you'll get the other one. Two. So, I mean, that'll be the left side right there. One, two, three. So this will be for Jack. This will be for Allen. All right. So I was a dumb.  Like, you can just peel that off right there. And they just wrap it. It's really easy. So my apologies to tops. All right. So the second card is the auto. So let's set that right there. And then let's take a quick glance at the rest. Pretty cool set, I think. A lot of nice stuff. And of course, each of these boxes have a dual autograph behind it. So behind Bryce Harper and Mike Trout is Juan Soto and Christian Yelich. One out of 25. Nice dual autograph. Yeah, they're all stickers. They're all going to be stickers. Still nice though. One out of 25. There you go. So that's for Allen. Next one for Jack B. Next one. You're the rest here. All right, Jack. You've got seven out of 25. A couple old school guys here. We've got the Hawk, Andre Dawson, and Tony Perez. And out of 25 as well. Nice. Is there another card behind there? I didn't snag. There we go. We've got another one box clearly authentic in the store with a chance to win these dual autographs, ladies and gentlemen. Some pretty great stuff. I don't think I've seen this dual auto yet. And I think 25 is the lowest number I've seen. I think they could go lower. I'm not sure about that. But I think they could go lower. So check it out on Jasveyscasebrakes.com. I'm Joe. I'll break more with you next time. Bye-bye.


So thanks. I'm sensitive to the fact that I'm one of the few things standing between you guys and going home So I'll try to be officially lunch is standing between you two So there is there is a lunch to which even is a greater imperative perhaps, but Our oversight group has been as you can see talking about the future of these meetings and one topic that has come up a few times is what's happening in the international community and I think The the the context is of course that we are not alone in our efforts to advance genomics into health and society that Probably we cannot afford to be insular and if we wish to we have an opportunity perhaps to take a leadership role on the in the international community so We we address this topic because genomic medicine doesn't have any particular Boundaries as we've talked about it doesn't have a have disease related boundaries, but certainly does not have National boundaries and as we are all aware that there have been significant investments, and I may not have listed them all here creating hubs for genome technologies across The globe and the as as was the case I think with the impetus for these meetings are getting all of you together the opportunity to explore the synergies redundancies and the potential to move the advance the field forward is something that's on our minds when it pertains to the International a community as well So could we perhaps create a more global agenda for genomic medicine as it pertains to the health globally not global health As it's normally thought about but certainly could impact that topic as well I thought I would list here some Initiatives that have come to our attention in our oversight group meetings Some of you are probably aware of many of them Perhaps personally involved in some of them and what I what I hope to do what I'd like to do is just give you a brief snapshot of Of these five over the next few minutes, but I also want to recognize that there are Many other efforts that have not necessarily been topics of conversation in our oversight group and here these are some of the Nationalities that have come to our attention involved in the genomic medicine field and while I'm on the side I'd really like to also extend a welcome and To dr. Milano from Tokyo from the Human Genome Center. So clearly we have had outreach To the international community already and we're grateful for your being here to be participant in this in this meeting So I think one of the things that we're going to be looking for you to do is help us understand What who might be the participants in such a meeting which currently is not scheduled with a definitive date But probably will happen some time in the fall. So first I think in our discussions We've recognized that the Canadians and specifically the genome Canada initiative to advance genomics and personalized medicine into health care through a very large Large project RFA for 2012 called genomic genomics and personalized medicine. It's probably one of the more advanced Countries leading the efforts. You can see the tenor of the RFA here And this probably sounds like something very much like our own Demonstration projects to support projects that will demonstrate how genomic space research can contribute to more evidence-based approach to health and improving cost Effectiveness of the health care system the total funding for this Projects that will initiate this year is around a hundred and thirty million dollars forty million from the government genome Canada Todd 22 and a half million through the Canadian Institute for Health Research and some other small funding agencies and importantly The emphasis of these a requirement of these applications was Co-funding generally through commercial entities to supply up to at least 50% of the funding opportunity The the decisions were made last month. I don't know what they were but about 10 to 12 projects are slated to initiate very shortly I had the opportunity to attend a workshop in Israel this fall Sponsored by the National Institute for Health Research policy the agenda for the workshop as you can see here also has some resonance with Topics that we've discussed here many times how to assess the value proposition for personalized medicine Both from an economic point of view and developing the evidence based through comparative effectiveness research the policy agenda And also what are some of the barriers to implementing implementing personalized medicine the output of that workshop? is a white paper that Has elements that again resonate with our top topics that we've discussed here the knowledge gap in educating health professionals Obviously the topic of this meeting how to create a deris data sharing a framework within Israel collaborative frameworks as well And all of this is going towards to the Ministry of Health as a proposal to Support and provide resources to enable genomic and personalized medicine Within Israel and one of the interesting things about that particular environment is that 100% of the population is covered by four HMOs and the HMOs appear to be very willing to collaborate with each other on really under on gathering data to generating the evidence and also Creating the economic models that support the advancement of genomics in healthcare The we came we last about a year ago the United Kingdom published a strategy document To the best of my knowledge. I don't know that any of this has truly been implemented, but again Many themes in the UK's strategy for genomics in healthcare are similar to our own How do we get it adopted mainstream? What are the translational pathways? What's the infrastructure bioinformatics as a is and training our clear themes and the policy agenda? As well, so, you know, it's it's interesting to see how Many international communities are working in parallel As was mentioned earlier Today or yesterday Dan Rodin is on is on loan to the European Science Foundation at a meeting in which they're discussing these very Similar types of initiatives This was a report that came to our attention just several months ago personalized medicine in the European citizen so again again illustrative also some of some of the fragmentation the UK has its own strategy the rest of Europe has has theirs and although the words are slightly different on on the focal points for the ESF initiative I think if you look at them carefully, they are a very synonymous with what the UK and what we're doing here in the US Are really thinking about doing again. We'll hear back from Dan Hopefully about his experience there, but the early reports from his presentation about what we're doing indicated There was a lot of interest in in partnering I also wanted to Give you a sense of what the world economic form is thinking about this topic Lord our Darcy was chair of a genetics and medicine committee for a year or so At the WEF and they published a white paper result in the New England Journal of Medicine about 12 or 14 months ago that Articulated the output of that sort of primordial committee on this topic Again several that several of the themes that you see are things that we've discussed And certainly touched on in many of these meetings that committee has been reassembled or actually disbanded and then Reassembled this summer To a global agenda committee on personalize and precision health as you can see it has Somewhat global representation. There's a high. There's a strong footprint from the United States Francis Collins And Peggy hamburger on this committee and Victor Zau Chairs it and the the the WEF met last week in Davos as some of you know and these Were some of the outputs of that meeting on this topic. So there were three initiatives that were provisionally approved for resources from the Board of Governors from the World Economic Forum the first one was to address the global to understand how personalized medicine and genomic medicine Technologies might be helpful in addressing the global economic burden of disease this relates to another initiative at the WEF which is called sustainable health systems in which a A model of of Healthcare economics and the disease drivers of the economic burden in several countries was articulated over the last year That report has been presented and the question is are there approaches that can synergize with alleviating that health economic burden of disease in various global economies so a number of committee members from our global agenda council will be Creating a white paper on the value proposition of personalized health care approaches in various world economies That's obviously sounds quite synonymous or quite Synergistic with what the World Economic Forum might want to do the second Area that is also Was widely discussed in at the global agenda council was a big data data sharing data sharing frameworks Charles Sawyer's is a member of the committee. He chaired the Iowan panel on Toward precision medicine in which this topic was very much a thread through the entire through its entirety and Francis Collins I think has had a significant impact on Helping us think through this so the idea essentially which seems to have been approved is to With a knowledge partner and that's a that's WEF terminology for the likes of McKinsey Deloitte or Price Waterhouse to Really understand the landscape and the gaps That would exist to try to create a global data commons that would Accumulate a lot of genomic and health care related information. So again, this sounds very much similar Synodistic with big data and other topics that we've we've talked about here and then the last topic that was discussed and Again provisionally approved was was trying to begin to understand The what is needed to achieve greater? Harmonization and alignment in both regulatory approval strategies as well as reimbursement strategies for genome-based Technologies and I'm sure that Peggy Hamburg also had a strong hand in Putting this agenda item forward so the the output which we Anticipate seeing over the next year is a workshop of the global community to address some of these policy issues and perhaps a White paper that will articulate what those policy alignment strategies would be So I think I've given you in the in the last few minutes a snapshot of some of the gears that are turning on the international Scene that are very much related to our agenda here. So We've we we haven't fleshed this out in any great detail That was one of the things we realized last night at dinner Why we couldn't really conceive of putting on a meeting of the international community in May without having Engaged all of you as well as even ourselves and trying to think about what that agenda would look like I think the answer to this question about should we is probably answered yes And Eric may want to comment, but he certainly has told us that he's been The subject of a lot of inquiries on the international from the international community about how to really engage with NHGRI and the activities of this group Why should we do this? I think Identifying as I said earlier the Commonalities and addressing barriers and solutions synergies and eliminating redundancy The kinds of things we've talked about in terms of standardization of of data standardization of CDS standardization of Genomic variants and a number of other Technologies could certainly be brought to the to another level and the global community is probably also addressing that the notion of international pilot projects of which genome Canada has already taken a First step is something that we could also perhaps leverage some of the activities that we've talked about here and bring in international resources to To help enable those public-private partnerships understanding the economic models the policy issues and Also the ability to work in And perhaps environments that might make it even easier to capture the data single-state single-payer types of countries or Environments where that data is read up more readily available than perhaps in the fragmented system in which we currently operate Here so I think you can appreciate the you know the litany of potential ideas that might Emerge from such a meeting. I'm sure you could think of many of your own We've certainly thought about Who should we invite? I think there's a on on one hand We would probably want to attract the leaders of the ministries of health that are making the policy decisions to fund these types of things But they may be not well connected enough to the science to Speak cogently about what the scientific agenda should be so we thought about actually trying to perhaps bring both flavors to a meeting like This that's not etched in stone and also we would Also choose to have this meeting also in Washington DC for obvious reasons So I'll I'll stop there and open it up for discussions questions or comments Okay, thanks Jeff Howard Thanks Jeff what I would add that the Emerging countries as they're called We should also be thinking about it the the development countries have problems way beyond genomics But at least with pharmacogenomics, which I know is only a small part of it I've been shocked at the level of implementation. That's already gone on in terms of routine use of pharmacogenomics in Thailand and in China and You know, you think about it as something you know, we're not doing it here. No one's doing it They're doing it routinely and it's paid for for things like avoiding Stevens-Johnson syndrome with Noverapine carbamazepine alpyrinol in Thailand and then in China there are both commercial and Government funded, I guess you they're all the same over there that it is Now in major hospitals, so there they're There really is a lot more going on out there than I I realized And we can really try to pull that in because I think we could actually learn from what they're doing as opposed to The assumption that they will be learning from us Yeah, well, that's a that's a fantastic point And I would mention, you know that I think on one of my earlier slides I didn't I didn't mention specifically but the H3 Africa initiative is one of those Initiatives to bring genomics into develop the developing world in a sense I think would be Resident you know constant with what you just said We know that YT Chen in Taiwan has been highly successful in executing on Genomic genetic guided clinical trials for things like carbamazepine and has Changed the way that practice medicine in some of those countries And maybe you'd like to just mention a couple of words on PG any your initiative in this in this area I think I had the first slide So what We've been using pharmacogenomics in a kind of a weird way we've been working with developing countries So not the emerging ones as much but the developing countries that may not have clean water or electricity But they're one of their major decisions is choosing their national formulary. And so They rely predominantly on white data for because With our recent FDA analysis 87% of the pivotal FDA data comes from white patients. And so if you're in Ghana or In Myanmar, you're relying on white data to try to make your national formula decision So we take pharmacogenetic risk risk data from local populations Merge that with the the white data from Geneva to come up with a national formulary recommendation for each individual country And so it's population or public health genomics not individual patient genomics But it's been a great experience and it's caused the ministries of health to think of genomics in a different way because they're scared of Braca and Alzheimer's or whatever, but they're not scared of safe medicine. And so it's been kind of a way of introducing that as well Thanks Howard. Great John. I Think the our international colleagues face very different Implementation barriers than we do and in some situations There are fairly large databases already put together of clinical material that I hope those are those scientists will be In part of this and invited like 500 whole exomes that have been for a specific phenotype those kinds of Studies could provide huge insights for us Yeah, I well first of all, thank you I would I would say that one of the things of we would encourage all of you to do is to Send us your ideas of what we might want to highlight at such a such a venue. So if you know of specific projects or specific, you know collaborators of yours or people that Could make a significant contribution in illuminating the commonalities as well as the diversity and heterogeneity of the challenges that we face We'd like to hear from you because we've just you know We're just we're very myopic in some ways of our own But I think we can leverage the crowd here in terms of your I know you a lot of you have frequent flower miles that Justify that so that you've you've traveled to a lot of these places you collaborate with a lot of international Groups and we want to make sure that we highlight Those that are really helping to drive this agenda. So by all means Before I call on Mike, I might just comment that that we do probably or maybe this is a question. Do we? Want to have an emphasis more on the implementation side than the discovery side and and I think you know To the degree that they're doing implementation in actual patient care I think that would be the kinds of projects that you're talking about But they're both academically oriented and then there are some very obvious businesses that are quite international and their scope that Are making major moves in terms of trying to capture as much of the world's business as possible Yeah, I should well that's a I think that's a good point and we've and many of the themes Topics that we've talked about here the business Opportunities of are not having been on our you know our major focus. So we might Take that as a separate topic altogether but I think as as health care delivery systems struggle with the the ability to put this into their work streams and to Develop the the value proposition on a number of different levels patient provider system economic That's really we want. I think that's the place that we want to focus our Most of our attention so the extent that this that's there that the businesses are enabling of that that would certainly that would be An opportunity I think Okay, Mike you had a comment Briefly that I've been to a couple of these international meetings and there there is a lot of interest in WHO in resourcing some of the developing countries That's all they will put their money towards as the developing countries And then UNESCO has established it's around a particular project Which I won't talk about the viability of that particular project But they've established clinical annotation of the genome as one of their highest priority projects internationally I was at a meeting there last summer in Paris with that UNESCO where there they've been trying to develop this It's going to be exceedingly Useless with the United States at this point in time because we're out of UNESCO for funding purposes because of having brought the Palestinians in the UNESCO and our laws that don't allow us to play in places where they play And they may we may get over that hump But for the rest of the world that UNESCO is likely to be able to resource some of this stuff and is very interested in and working through their connections to other countries to develop genomic annotation and understand the You know the genomic backgrounds in many of these countries as Howard alluded to With his pharmacogenetics project because these that's you know, there's some of the variation is going to be around those backgrounds on which the stuff's operating Thanks. Thanks other comments. I have one As you begin to think about the audience with the implementation as the perspective of the meeting And I know the agenda may be too large for this But also consider the varied health care professionals that are implementing it across those countries We have a very good collaboration with the United Kingdom nursing group, which is extremely active over there So just a thought for future consideration Thank you, and it could be that some of the things that we've talked about even in this meeting yesterday about health professional Education might take on an international flavor at some point. So that might be one of the ways to bring in that Concept thanks for raising it and we may want want to ask up You know a planning group to kind of define what the goals for this meeting would be because because obviously, you know, there's there's an yeah Okay, so so it seems as though we have Reasonable agreement that this is something to go forward with any any objections or concerns that haven't been voiced Great. All right, and I think we can thank Jeff and we're getting close to the end of our of our effort here One thing that was suggested in terms of heading back to the airport I mean, sorry, we're in the airport heading back to your terminal because it's an enormous airport So we're in in terminal C It seems as though you need almost to take the shuttle from the hotel although apparently Howard says there's a walking route That's that's up and downstairs and that really okay So follow Howard if you wanted if you want to do that if you do want to take the shuttle It leaves every 20 minutes on the on the hour But of course there are other 20 minutes at art. So there's nine nine twenty or two two twenty two forty Do be considerate of those who have earlier flights and kind of let them take the first shuttles if they get full I did want to thank Hartley Jean Passimani and Mark Williams for putting together this program and especially Richard Fogli Who did so much work and making it all work. So thank you Richard and Any closing comments from dr. Williams. No, I think just thanks to everyone. I mean the success of these meetings is basically due to the participation in the engagement and we recognize that this is for the most part all being done as volunteerism and We think that it's been because we've been Sensitive to what the group has really wanted to do that we in fact continue to accrue more and more attendees Which in some sense is a metric of the success and we hope that that will continue in the future and a special thanks to all of the presenters those that are still here and those that have already Headed back home and thanks to those of you who have in the course of the meeting Volunteered to participate in some other aspects of the work that we're doing so lunch is available and safe travels to all


Hi and welcome to the session. Today we will learn about area of closed figures. So first of all let's see what is the area, the amount of surface enclosed by a closed figure is called its area. So here in this rectangle this much portion is the area of this rectangle and in this circle this portion is the area of this circle. Now let's learn how to find out the area of a figure using a square paper. Well we have a square paper and we need to find out the area of this triangle using this square paper and we can see these squares like this one. So if we are given one square then the area of this whole square will be one square units will be equal to one square units for this square which is more than half. The area will be again one square. So here let us write more than half will be equal to one square units for the square which is exactly half the area of square units. So here we have for exactly half will be equal to half that is 1 by 2 square units and the squares which are less than half will be ignored that is their area will be taken as 0 square units will be equal to 0 square units. So using these conventions we will find out the desired area let's go back to our figure that is the triangle. Here we have more than half is square half is squares so here the area of the triangle will be 6 into 1 square units as the area of whole square that is full square is 1 square unit so area of 6 squares will be 6 square units now the area of more than half square is 1 square unit and we have 6 more than half squares so again it will be 6 square units 0 half squares so it will be 0 square equal to 12 square units. Find out area of a rectangle is cd with its length denoted as l and breadth denoted as length into breadth. The angle is 4 centimeters and breadth of the rectangle is 3 centimeters to be equal to a unit that is a into a the area of a square with each side equal to 4 centimeters then its area will be equal to 4 centimeters into 4 centimeters 16 centimeters down the area of a rectangle and a square. Hope you must have understood the concepts I stay.